Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial

Marcia S Brose, Bruce Robinson, Steven I Sherman, Jolanta Krajewska, Chia-Chi Lin, Fernanda Vaisman, Ana O Hoff, Erika Hitre, Daniel W Bowles, Jorge Hernando, Leonardo Faoro, Kamalika Banerjee, Jennifer W Oliver, Bhumsuk Keam, Jaume Capdevila

The Lancet Oncology, 2021 Aug

Abstract link

Copyright © 2021 Elsevier Ltd. All rights reserved.